GlaxoSmithKline to set up €100 mln vaccine plant in Hungary
GlaxoSmithKline, one of Hungary's largest investors in the drugs industry, is to set up a high-tech vaccine production facility in Gödöllõ, 30 kilometers northeast of Budapest. GSK's €100 million investment is one of the company's key strategic investments in Europe. The new facility will apply the latest technological solutions and deliver the vaccines all over the world. The plant will be inaugurated on September 8. GSK has a staff of 360 people in Hungary. GlaxoSmithKline is to spend over Ft 22 billion (€79.5 million) to upgrade vaccine production capacities at its Gödöllõ facility that it bought from Human Rt. The regional R&D centre has an annual budget of Ft 370 million (€1.34 million) and involves 1,300 patients. The investment volume as well as the number of R&D patients are to be more than doubled by 2007. (MTI-Eco)
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.